Literature DB >> 27815034

Continuous corticosterone delivery via the drinking water or pellet implantation: A comparative study in mice.

Sylvia J Gasparini1, Marie-Christin Weber2, Holger Henneicke3, Sarah Kim4, Hong Zhou4, Markus J Seibel5.   

Abstract

In order to investigate the effects of glucocorticoid excess in rodent models, reliable methods of continuous glucocorticoid delivery are essential. The current study compares two methods of corticosterone (CS) delivery in regards to their ability to induce typical adverse outcomes such as fat accrual, insulin resistance, sarcopenia and bone loss. Eight-week-old mice received CS for 4weeks either via the drinking water (25-100μgCS/mL) or through weekly surgical implantation of slow release pellets containing 1.5mg CS. Both methods induced abnormal fat mass accrual, inhibited lean mass accretion and bone expansion, suppressed serum osteocalcin levels and induced severe insulin resistance. There was a clear dose dependant relationship between the CS concentrations in the drinking water and the severity of the phenotype, with a concentration of 50μg CS/mL drinking water most closely matching the metabolic changes induced by weekly pellet implantations. In contrast to pellets, however, delivery of CS via the drinking water resulted in a consistent diurnal exposure pattern, closely mimicking the kinetics of clinical glucocorticoid therapy. In addition, the method is safe, inexpensive, easily adjustable, non-invasive and avoids operative stress to the animals. Our data demonstrate that delivery of CS via the drinking water has advantages over weekly implantations of slow-release pellets. A dose of 50μg CS/mL drinking water is appropriate for the investigation of chronic glucocorticoid excess in mice. Crown Copyright Â
© 2016. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Corticosterone delivery; Glucocorticoid-induced dysmetabolism; Hypercortisolism; Insulin-resistance; Osteoporosis; Sarcopenia

Mesh:

Substances:

Year:  2016        PMID: 27815034     DOI: 10.1016/j.steroids.2016.10.008

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  10 in total

1.  Role of Mineralocorticoid Receptor in Adipogenesis and Obesity in Male Mice.

Authors:  Daniel Ferguson; Irina Hutson; Eric Tycksen; Terri A Pietka; Kevin Bauerle; Charles A Harris
Journal:  Endocrinology       Date:  2020-02-01       Impact factor: 4.736

2.  Chronic corticosterone shifts effort-related choice behavior in male mice.

Authors:  Andrew Dieterich; Karina Stech; Prachi Srivastava; Jay Lee; Aitesam Sharif; Benjamin Adam Samuels
Journal:  Psychopharmacology (Berl)       Date:  2020-04-18       Impact factor: 4.530

3.  Androgens sensitise mice to glucocorticoid-induced insulin resistance and fat accumulation.

Authors:  Sylvia J Gasparini; Michael M Swarbrick; Sarah Kim; Lee J Thai; Holger Henneicke; Lauryn L Cavanagh; Jinwen Tu; Marie-Christin Weber; Hong Zhou; Markus J Seibel
Journal:  Diabetologia       Date:  2019-05-16       Impact factor: 10.122

Review 4.  Spaceflight Stressors and Skin Health.

Authors:  Wilhelmina E Radstake; Bjorn Baselet; Sarah Baatout; Mieke Verslegers
Journal:  Biomedicines       Date:  2022-02-02

5.  Metabolic and skeletal homeostasis are maintained in full locus GPRC6A knockout mice.

Authors:  Christinna V Jørgensen; Sylvia J Gasparini; Jinwen Tu; Hong Zhou; Markus J Seibel; Hans Bräuner-Osborne
Journal:  Sci Rep       Date:  2019-04-12       Impact factor: 4.379

6.  11β-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy.

Authors:  C G Fenton; C L Doig; S Fareed; A Naylor; A P Morrell; O Addison; C Wehmeyer; C D Buckley; M S Cooper; G G Lavery; K Raza; R S Hardy
Journal:  Arthritis Res Ther       Date:  2019-08-16       Impact factor: 5.156

7.  Local steroid activation is a critical mediator of the anti-inflammatory actions of therapeutic glucocorticoids.

Authors:  Chloe Fenton; Claire Martin; Rachel Jones; Adam Croft; Joana Campos; Amy J Naylor; Angela E Taylor; Myriam Chimen; Mark Cooper; Gareth G Lavery; Karim Raza; Rowan S Hardy
Journal:  Ann Rheum Dis       Date:  2020-11-08       Impact factor: 19.103

Review 8.  Bad to the Bone: The Effects of Therapeutic Glucocorticoids on Osteoblasts and Osteocytes.

Authors:  Manuel Gado; Ulrike Baschant; Lorenz C Hofbauer; Holger Henneicke
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-31       Impact factor: 5.555

9.  Chronic glucocorticoid exposure causes brown adipose tissue whitening, alters whole-body glucose metabolism and increases tissue uncoupling protein-1.

Authors:  Jocelyn S Bel; T C Tai; Neelam Khaper; Simon J Lees
Journal:  Physiol Rep       Date:  2022-05

10.  Therapeutic glucocorticoids prevent bone loss but drive muscle wasting when administered in chronic polyarthritis.

Authors:  C G Fenton; J M Webster; C S Martin; S Fareed; C Wehmeyer; H Mackie; R Jones; A P Seabright; J W Lewis; Y C Lai; C S Goodyear; S W Jones; M S Cooper; G G Lavery; R Langen; K Raza; R S Hardy
Journal:  Arthritis Res Ther       Date:  2019-08-01       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.